









1112Ex Vivo T Cell Depletion of Allogeneic PBSC as Acute
and Chronic GVHD Prophylaxis after Myeloablative
HCT: Time to Reconsider?
Vincent T. HoAlthough established as an effective method for
mitigating graft-versus-host disease (GVHD) after
allogeneic hematopoietic cell transplantation (HCT), ex
vivo donor T cell depletion (TCD) has yet to gain wide
application. Randomized clinical trials to date have
shownTCDreduces acuteGVHD(aGVHD), but offers
no survival advantage over conventional pharmacologic
GVHD prophylaxis [1,2]. The benefits of TCD in
GVHD reduction were often counterbalanced by an
increased risk of relapse, graft failure, posttransplant
lymphoproliferative disease, and infections. Further,
these studies primarily involved TCD of bone marrow
grafts using inefficient and time-consuming antibody-
based and/or mechanical separation techniques. The
landscape of HCT has changed significantly over the
past decade. More patients are now receiving mobilized
peripheral blood stem cell (PBSC) instead of marrow
grafts. With higher CD341 and CD31 content in
PBSC, the risk of graft failure is diminished, and there
is a greater risk of acute and particularly chronic
GVHD (cGVHD). Posttransplant supportive care mea-
sures, especially pertaining to infection monitoring and
treatments, are vastly improved. Acutemyelogenous leu-
kemia (AML) has replaced chronic myeloid leukemia
(CML) as the leading indication forHCT. A recentmul-
ticenter trial has already demonstrated that addition of
rabbit antithymocyte globulin (ATG) (Fresenius Biotech
GmbH, Germany) as in vivo TCD to cyclosporine/
methotrexate aftermatched unrelated donor transplanta-
tion (82%PBSC, 18%marrow) is associated with signif-
icant reduction in aGVHD and cGVHD [3]. As such,
couldPBSCthenbeabetter venue to test again themerits
of ex vivoTCDaftermyeloablativeHCT?The advent of
standardized and efficient CD341 selection columns
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engineer grafts containing 103-104 CD31/kg, a full 1-2
logs below the thresholdwhere posttransplant exogenous
immune suppression is necessary in matched sibling
transplantation [4]. The question is: With this extent of
T cell depletion, how would immune reconstitution
and the graft-versus-leukemia (GVL) effect be affected?
In this issue, 2 separate phase II prospective trials
involving a total of 79 patients show very promising
results for myeloablative transplantation using ex
vivo CD341 selected PBSC grafts [5,6]. The striking
findings are that aGVHD and cGVHD control
are excellent despite no posttransplant immune
suppression, and importantly, disease relapse is very
respectable even with extended follow-up. In the study
by Jakubowski et al. [5], which included 35 patients re-
ceiving matched or mismatched unrelated donor grafts
after a fludarabine/thiotepa/fractionated total-body ir-
ridiation (TBI)/ATG conditioning, the aGVHD and
cGVHD incidence were 9% and 29%, respectively,
and cumulative incidence of relapse was only 6%. Im-
mune reconstitution studies demonstrated that num-
bers of circulating CD81 cells normalized and CD41
cells surpassed 200/mL at a median of 4-6 months
and 6-9 months, respectively. In the report by Devine
et al. [6], which is a multicenter trial conducted
through the BMT CTN, 44 patients with AML in
CR1 or CR2 received CD341-selected PBSC grafts
from matched sibling donors after cytoxan/thiotepa/
fractionated total body irradiation/anti-thymocyte
globulin (TBI/ATG). The grade 2-4 aGVHD inci-
dence was 22.7%, and the incidence of cGVHD was
only 19% (7% extensive) at 24 months posttransplant.
Cumulative incidence of relapse was 23% at 3 years.
Among patients transplanted in CR1, disease-free
survival at 3 years was 58%, which appears to be in
keeping with survival data in HCT using conventional
GVHD prophylaxis. Importantly, the incidence of
bacterial, fungal, and cytomegalovirus (CMV) infec-
tions appear to be comparable to conventional PBSC
transplantation, with the exception of Epstein-Barr
virus (EBV) reactivation and PTLD manageable with
rituximab. Together, these 2 studies suggest that
TCD of PBSC could be a viable means for reducing
both aGVHD and cGVHD without compromising
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PBSC transplantation. Although quality-of-life
metrics were not used in these trials, it is tempting
to speculate that the drastic reduction in cGVHD
could translate to increased patient satisfaction and,
ultimately, healthcare cost savings. Phase III studies
testing ex vivo TCD with CD341 selection after
myeloablative PBSC transplantation appear to be
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